Page 2151 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 126 Molecular Basis of Blood Coagulation 1905.e7

300. Girard TJ, Warren LA, Novotny WF, et al: Functional significance of 329. Brummel-Ziedins KE, Whelihan MF, Gissel M, et al: Thrombin gen-
the Kunitz-type inhibitory domains of lipoprotein-associated coagula- eration and bleeding in haemophilia A. Haemophilia 15:1118, 2009.
tion inhibitor. Nature 338:518, 1989. 330. Moncada S, Higgs EA, Vane JR: Human arterial and venous tissues
301. Baugh RJ, Broze GJ, Jr, Krishnaswamy S: Regulation of extrinsic generate prostacyclin (prostaglandin x), a potent inhibitor of platelet
pathway factor Xa formation by tissue factor pathway inhibitor. J Biol aggregation. Lancet 1:18, 1977.
Chem 273:4378, 1998. 331. Esmon CT, Owen WG: Identification of an endothelial cell cofactor
302. Novotny WF, Palmier M, Wun TC, et al: Purification and properties for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA
of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 78:2249, 1981.
78:394, 1991. 332. Busch C, Owen WG: Identification in vitro of an endothelial cell
303. Rapaport SI: The extrinsic pathway inhibitor: a regulator of tissue surface cofactor for antithrombin III. Parallel studies with isolated
factor-dependent blood coagulation. Thromb Haemost 66:6, 1991. perfused rat hearts and microcarrier cultures of bovine endothelium. J
304. Orfeo T, Brufatto N, Nesheim ME, et al: The factor V activation Clin Invest 69:726, 1982.
paradox. J Biol Chem 279:19580, 2004. 333. Turk B, Brieditis I, Bock SC, et al: The oligosaccharide side chain on
305. Brummel KE, Paradis SG, Butenas S, et al: Thrombin functions during Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases
tissue factor-induced blood coagulation. Blood 100:148, 2002. the heparin affinity of the inhibitor by affecting the heparin-induced
306. Mann KG, Brummel-Ziedins K, Orfeo T, et al: Models of blood conformational change. Biochemistry 36:6682, 1997.
coagulation. Blood Cells Mol Dis 36:108, 2006. 334. Esmon CT, Esmon NL, Harris KW: Complex formation between
307. Coughlin SR, Vu TK, Hung DT, et al: Characterization of a functional thrombin and thrombomodulin inhibits both thrombin-catalyzed
thrombin receptor. Issues and opportunities. J Clin Invest 89:351, 1992. fibrin formation and factor V activation. J Biol Chem 257:7944, 1982.
308. Naito K, Fujikawa K: Activation of human blood coagulation factor 335. Esmon NL, Carroll RC, Esmon CT: Thrombomodulin blocks the
XI independent of factor XII. Factor XI is activated by thrombin and ability of thrombin to activate platelets. J Biol Chem 258:12238, 1983.
factor XIa in the presence of negatively charged surfaces. J Biol Chem 336. Bajzar L: Thrombin activatable fibrinolysis inhibitor and an antifibri-
266:7353, 1991. nolytic pathway. Arterioscler Thromb Vasc Biol 20:2511, 2000.
309. Davey MG, Luscher EF: Actions of thrombin and other coagulant and 337. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated
proteolytic enzymes on blood platelets. Nature 216:857, 1967. protein C in clots formed from plasma is TAFI-dependent. Blood
310. Lorand L, Konishi K: Activation of the fibrin stabilizing factor of 88:2093, 1996.
plasma by thrombin. Arch Biochem Biophys 105:58, 1964. 338. Tracy RP: Thrombin, inflammation, and cardiovascular disease: an
311. Mann KG, Jenny RJ, Krishnaswamy S: Cofactor proteins in the epidemiologic perspective. Chest 124:49S, 2003.
assembly and expression of blood clotting enzyme complexes. Annu 339. Robbins KC, Summaria L, Hsieh B, et al: The peptide chains of human
Rev Biochem 57:915, 1988. plasmin. Mechanism of activation of human plasminogen to plasmin.
312. Fay PJ: Subunit structure of thrombin-activated human factor VIIIa. J Biol Chem 242:2333, 1967.
Biochim Biophys Acta 952:181, 1988. 340. Pannell R, Gurewich V: Activation of plasminogen by single-chain
313. Whelihan MF, Zachary V, Orfeo T, et al: Prothrombin activation in urokinase or by two-chain urokinase–a demonstration that single-chain
blood coagulation:the erythrocyte contribution to thrombin genera- urokinase has a low catalytic activity (pro-urokinase). Blood 69:22,
tion. Blood 120:3837–3845, 2012. 1987.
314. Ahmad SS, Rawala-Sheikh R, Walsh PN: Components and assembly 341. Dichek D, Quertermous T: Thrombin regulation of mRNA levels of
of the factor X activating complex. Semin Thromb Hemost 18:311, tissue plasminogen activator and plasminogen activator inhibitor-1 in
1992. cultured human umbilical vein endothelial cells. Blood 74:222, 1989.
315. van ’t Veer C, Mann KG: Regulation of tissue factor initiated thrombin 342. Diamond SL, Eskin SG, McIntire LV: Fluid flow stimulates tissue
generation by the stoichiometric inhibitors tissue factor pathway inhibi- plasminogen activator secretion by cultured human endothelial cells.
tor, antithrombin-III, and heparin cofactor-II. J Biol Chem 272:4367, Science 243:1483, 1989.
1997. 343. Hoylaerts M, Rijken DC, Lijnen HR, et al: Kinetics of the activation
316. Hockin MF, Jones KC, Everse SJ, et al: A model for the stoichiometric of plasminogen by human tissue plasminogen activator. Role of fibrin.
regulation of blood coagulation. J Biol Chem 277:18322, 2002. J Biol Chem 257:2912, 1982.
317. Cawthern KM, van’t Veer C, Lock JB, et al: Blood coagulation in 344. Zamarron C, Lijnen HR, Collen D: Kinetics of the activation of plas-
hemophilia A and hemophilia C. Blood 91:4581, 1998. minogen by natural and recombinant tissue-type plasminogen activator.
318. Butenas S, Brummel KE, Branda RF, et al: Mechanism of factor VIIa- J Biol Chem 259:2080, 1984.
dependent coagulation in hemophilia blood. Blood 99:923, 2002. 345. Loscalzo J: Structural and kinetic comparison of recombinant human
319. Tracy PB, Nesheim ME, Mann KG: Platelet factor Xa receptor. Methods single- and two-chain tissue plasminogen activator. J Clin Invest
Enzymol 215:329, 1992. 82:1391, 1988.
320. Nesheim ME, Taswell JB, Mann KG: The contribution of bovine 346. Gaffney PJ, Brasher M: Subunit structure of the plasmin-induced deg-
Factor V and Factor Va to the activity of prothrombinase. J Biol Chem radation products of crosslinked fibrin. Biochim Biophys Acta 295:308,
254:10952, 1979. 1973.
321. Orfeo T, Brummel-Ziedins KE, Gissel M, et al: The nature of the stable 347. Francis CW, Marder VJ, Barlow GH: Plasmic degradation of crosslinked
blood clot procoagulant activities. J Biol Chem 283:9776, 2008. fibrin. Characterization of new macromolecular soluble complexes and
322. Butenas S, Cawthern KM, van’t Veer C, et al: Antiplatelet agents in a model of their structure. J Clin Invest 66:1033, 1980.
tissue factor-induced blood coagulation. Blood 97:2314, 2001. 348. Marder VJ: Physicochemical studies of intermediate and final products
323. Butenas S, Branda RF, van’t Veer C, et al: Platelets and phospholipids of plasmin digestion of human fibrinogen. Thromb Diath Haemorrh
in tissue factor-initiated thrombin generation. Thromb Haemost 86:660, 39:187, 1970.
2001. 349. Larrieu MJ, Marder VJ, Inceman S: Effects of fibrinogen degradation
324. Mann KG, Butenas S, Brummel K: The dynamics of thrombin forma- products on platelets and coagulation. Thromb Diath Haemorrh Suppl
tion. Arterioscler Thromb Vasc Biol 23:17, 2003. 20:215, 1966.
325. Mann KG, Krishnaswamy S, Lawson JH: Surface-dependent hemosta- 350. Reilly CF, Hutzelmann JE: Plasminogen activator inhibitor-1 binds to
sis. Semin Hematol 29:213, 1992. fibrin and inhibits tissue-type plasminogen activator-mediated fibrin
326. Butenas S, Mann KG: Kinetics of human factor VII activation. Bio- dissolution. J Biol Chem 267:17128, 1992.
chemistry 35:1904, 1996. 351. Sharp AM, Stein PE, Pannu NS, et al: The active conformation of plas-
327. Rand MD, Lock JB, van’t Veer C, et al: Blood clotting in minimally minogen activator inhibitor 1, a target for drugs to control fibrinolysis
altered whole blood. Blood 88:3432, 1996. and cell adhesion. Structure 7:111, 1999.
328. Brummel-Ziedins KE, Branda RF, Butenas S, et al: Discordant fibrin 352. Kawano T, Morimoto K, Uemura Y: Partial purification and properties
formation in hemophilia. J Thromb Haemost 7:825, 2009. of urokinase inhibitor from human placenta. J Biochem 67:333, 1970.